Although research is being conducted on Long COVID or Long COVID-19, whose symptoms continue for weeks and months after initial infection, there are very few ongoing clinical trials on treatments. Anecdotally, there has been what appears to be a successful treatment for Long Covid using Pfizer’s antiviral regimen Paxlovid.
A COVID-19 vaccine that can be produced locally in low-income and middle-income countries is yielding promising results in early clinical trials, researchers say. Other researchers believe that once the body has been “primed” by mRNA vaccines to recognize and attack the coronavirus, a booster containing purified versions of virus’ spike protein that could be given intranasally would have many advantages.
BlueWillow Biologics demonstrated the safety and immunogenicity in humans of the company’s intranasal technology, which CEO Chad Costley said is the only adjuvanted intranasal platform that is not virus-based.
The Omicron variant, which is spreading far faster than previous versions of the coronavirus, is not likely to help countries achieve so-called herd immunity against COVID-19 – in which enough people become immune to the virus that it can no longer spread – leading disease experts say.
A British public health study found that protection from either of the two most commonly used Covid-19 vaccines against the prevalent Delta variant of the coronavirus weakens within three months.
For many people, cats are cuddly and curious companions, but for at least 10 percent of adults they mean itchy skin, watering eyes and sneezing. This is primarily due to a protein called Fel d 1, and scientists are using a variety of approaches to try to change it.
Moderna Inc. filed for U.S. authorization to use the company’s Covid-19 vaccine in adolescents aged 12 through 17, potentially offering healthcare providers and pediatricians an easier-to-store shot ahead of the return-to-school season in the fall.
Pfizer Inc. will start a large study to test the company’s Covid-19 vaccine in children below 12 years and selected a dosing regime for the clinical trial.
President Joe Biden said it will be difficult for the United States to reach herd immunity, at least 75% of the population inoculated against the coronavirus, by the end of the 2021 summer.
Pfizer Inc. and partner BioNTech Se are developing a booster shot to protect against Covid-19 variants.